Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K.

Eur J Pharmacol. 1995 Dec 29;294(2-3):577-83.

PMID:
8750721
2.

Impact of psychostimulants on vesicular monoamine transporter function.

Fleckenstein AE, Hanson GR.

Eur J Pharmacol. 2003 Oct 31;479(1-3):283-9. Review.

PMID:
14612158
3.

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ.

Exp Neurol. 2003 Nov;184 Suppl 1:S68-79. Review.

PMID:
14597329
4.
5.

Dopamine transporters and neuronal injury.

Miller GW, Gainetdinov RR, Levey AI, Caron MG.

Trends Pharmacol Sci. 1999 Oct;20(10):424-9. Review.

PMID:
10498956
6.

[Function of monoamine neurotransmitter transporters].

Sasa M.

Nihon Rinsho. 2001 Aug;59(8):1457-64. Review. Japanese.

PMID:
11519142
7.
8.

The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins.

Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, Hazama M, Sora I.

FASEB J. 2000 Dec;14(15):2459-65. Review.

PMID:
11099463
9.

Human phenotypes and animal knockout models of genetic autonomic disorders.

Usera PC, Vincent S, Robertson D.

J Biomed Sci. 2004 Jan-Feb;11(1):4-10. Review.

PMID:
14730204
10.

A molecular glimpse of vesicular monoamine transporters.

Schuldiner S.

J Neurochem. 1994 Jun;62(6):2067-78. Review. No abstract available.

PMID:
7910628
11.

Imaging the vesicular monoamine transporter.

Frey KA, Koeppe RA, Kilbourn MR.

Adv Neurol. 2001;86:237-47. Review.

PMID:
11553983
12.

[Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].

Lorenzo-Sanz G, Sánchez-Herranz A.

Rev Neurol. 2011 Mar 1;52 Suppl 1:S103-8. Review. Spanish.

13.

Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice.

Tammimäki A, Männistö PT.

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):2-8. doi: 10.1111/j.1742-7843.2010.00647.x. Epub 2010 Nov 30. Review.

14.

Vesicular monoamine transporter 2: role as a novel target for drug development.

Zheng G, Dwoskin LP, Crooks PA.

AAPS J. 2006 Nov 10;8(4):E682-92. Review.

15.

Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE.

Pharmacol Rev. 2015 Oct;67(4):1005-24. doi: 10.1124/pr.114.010397. Review.

16.

Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles.

Henry JP, Scherman D.

Biochem Pharmacol. 1989 Aug 1;38(15):2395-404. Review. No abstract available.

PMID:
2667522
17.

The vesicular monoamine transporter 2: an underexplored pharmacological target.

Bernstein AI, Stout KA, Miller GW.

Neurochem Int. 2014 Jul;73:89-97. doi: 10.1016/j.neuint.2013.12.003. Epub 2014 Jan 4. Review.

18.

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Fleckenstein AE, Volz TJ, Hanson GR.

Neuropharmacology. 2009;56 Suppl 1:133-8. doi: 10.1016/j.neuropharm.2008.07.002. Epub 2008 Jul 10. Review.

19.

Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Lohr KM, Masoud ST, Salahpour A, Miller GW.

Eur J Neurosci. 2017 Jan;45(1):20-33. doi: 10.1111/ejn.13357. Epub 2016 Sep 2. Review.

PMID:
27520881
20.

The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.

Yulug B, Hanoglu L, Kilic E.

Med Chem. 2015;11(2):104-8. Review.

PMID:
25256242

Supplemental Content

Support Center